As More Products Get Priority Review, User Fee Cost Gap From Standard Review Is Narrowing
Executive Summary
US FDA’s priority review voucher fee will decrease again in FY 2022 as the cost of a priority assessment continues to trend closer to the cost of a standard assessment.